Vaxcyte, Inc.
PCVX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$60.43
KIRA · Stoqly’s AI analyst, in plain words
- Vaxcyte, Inc. lost $767M in fiscal 2025.
- Free cash flow was −$669M in fiscal 2025, — of revenue.
Market cap
$8.7B
P/E
—
Revenue
—
Net income
−$767M
Free cash flow
−$669M
Operating margin
—
Vaxcyte, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$767M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Vaxcyte, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Vaxcyte, Inc.
- CIK
- 0001649094
Vaxcyte, Inc. · PCVX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$100M | −$223M | −$402M | −$464M | −$767M |
| Diluted EPS | −$1.93 | −$3.44 | −$4.14 | −$3.80 | −$5.63 |
| Cash | |||||
| Cash from operations | −$121M | −$171M | −$297M | −$453M | −$656M |
| Capital expenditure | $6.6M | $5.8M | $16.1M | $22.4M | $13.7M |
| Free cash flow | −$128M | −$176M | −$313M | −$475M | −$669M |
| Share count change | 75.7% | 25.0% | 49.8% | 25.6% | 11.6% |
| Debt and strength | |||||
| Cash and short-term investments | $246M | $931M | $1.1B | $1.7B | $1.6B |
| Shareholders' equity | $284M | $954M | $1.2B | $3.3B | $2.7B |
| Current ratio | 8.9x | 23.3x | 7.5x | 12.8x | 7.9x |
| Interest coverage | −14,810.0x | −116,128.0x | — | — | — |
| Returns and quality | |||||
| Return on equity | −31.8% | −36.1% | −36.7% | −20.4% | −25.6% |
| Return on tangible equity | −35.2% | −23.4% | −32.4% | −14.0% | −28.5% |
| Altman Z'' | 6.9 | 21.7 | 7.8 | 17.6 | 7.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$12.4M
5 insiders
Of sales under plans
92%
$11.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vaxcyte, Inc. · PCVX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $60.43 a share, the company is worth $8.7B.
Source: SEC EDGAR XBRL filings (CIK 0001649094). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.